BIOPHTA has pioneered a novel approach to eye care by creating a cutting-edge pharmaceutical platform that enables continuous drug delivery.
BIOPHTA has raised $7.1M in total funding. The most recent round was Seed. The last funding was announced in June 2024.
BIOPHTA's investors include GO CAPITAL, Elaia, UI Investissement, HTL Biotechnology, Unither Pharmaceuticals.
BIOPHTA is headquartered in Paris, France.
BIOPHTA has pioneered a novel approach to eye care by creating a cutting-edge pharmaceutical platform that enables continuous drug delivery.
BIOPHTA is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BIOPHTA — Funding & Investors." VCBacked, June 3, 2024, https://www.vcbacked.co/company/biophta. Accessed September 10, 2026.
VCBacked. (2024). BIOPHTA — Funding & Investors. Retrieved September 10, 2026, from https://www.vcbacked.co/company/biophta
{{cite web |title=BIOPHTA — Funding & Investors |url=https://www.vcbacked.co/company/biophta |website=VCBacked |access-date=September 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated